Filing summary
Important identity and period discrepancy: The request identifies Tuhura Biosciences, Inc. and 2023 Q2, but the supplied filing is Kintara Therapeutics, Inc.’s Form 10-Q for the quarter and six months ended December 31, 2023. The summary below reflects the filing provided, not the requested company.
Business context and reporting period
Kintara is a clinical-stage cancer drug developer with no revenue to date. Its stated lead program is REM-001, a photodynamic therapy candidate for cutaneous metastatic breast cancer (CMBC). The filing covers the quarter ended December 31, 2023, and the six months then ended; amounts below are in U.S. dollars and thousands unless stated otherwise.
Financial performance and liquidity
| Metric | Quarter ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $111 | $1,970 |
| General and administrative expense | $908 | $2,011 |
| Net loss | $(1,023) | $(3,985) |
| Loss per share | $(0.24) | $(1.37) |
| Net cash used in operating activities | Not separately presented | $(3,434) |
- At December 31, 2023, cash and cash equivalents were $658, current assets $1,186, current liabilities $1,870, and working capital was negative $684. Total assets were $1,885 and total liabilities $2,049; stockholders’ equity was negative $164.
- Cash declined by $877 during the six months. Financing activities provided $2,577, including $2,476 net proceeds from the ATM offering and $105 from the Lincoln Park equity line. Investing activities used $20.
- The filing reports no revenue, so revenue growth and operating margins are not applicable. No conventional interest-bearing debt is shown on the balance sheet; liabilities include a $179 milestone payment liability.
Changes versus the prior comparable period
- Quarterly net loss narrowed to $1,023 from $3,454 a year earlier; six-month net loss narrowed to $3,985 from $8,050. Quarterly R&D fell 95% to $111, and six-month R&D fell 62% to $1,970. Management attributed lower spending mainly to reduced clinical development activity, lower share-based compensation, and the wind-down of VAL-083 work; REM-001 spending was expected to rise as its study restarted.
- Quarterly G&A fell 37% to $908, and six-month G&A fell 31% to $2,011, reflecting lower personnel costs, professional fees, and share-based compensation.
- Operating cash use was $3,434, versus $8,530 in the prior-year six-month period. Despite reduced cash use, cash on hand declined to $658 from $1,535 at June 30, 2023.
Outlook, risks, contingencies, and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year of the filing date. It expects to need significant additional funding and says there is no assurance financing plans will succeed. Failure to raise capital could require reductions or delays to development, or other major actions.
- Funding and dilution: The company had raised a further $6,108 net through ATM stock sales from January 1 through February 12, 2024. These proceeds provide additional liquidity but involve substantial share issuance. The filing reports 39,037,899 common shares outstanding as of February 12, 2024.
- Programs: Kintara terminated VAL-083 development after preliminary GBM AGILE results did not outperform the standard of care. It later assigned VAL-083 patent rights to Valent; Kintara is entitled to 5% of Valent Net Sales if Valent commercializes it. Kintara received a $2.0 million NIH grant over two years to support REM-001, and announced initiation of a 15-patient CMBC study on February 12, 2024.
- Nasdaq listing: The company was notified that it failed the stockholders’ equity requirement, with an extension to March 18, 2024, to evidence compliance, and separately failed the minimum bid-price requirement, with a deadline of June 10, 2024, to regain compliance. Delisting could impair liquidity and access to capital.
- Strategic review: In December 2023, the board initiated a process to explore strategic alternatives focused on maximizing stockholder value. No outcome is assured.
- Other items: The company recorded a $173 Series C stock dividend for the six-month period. It also disclosed termination costs for the VAL-083 CRO agreement, including a final $400 payment made after quarter-end. Management reported effective disclosure controls and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied filing is for Kintara Therapeutics, not Tuhura Biosciences, and covers the quarter ended December 31, 2023.
- Track cash use, remaining ATM capacity, share issuance and dilution, and whether further financing is secured.
- Monitor Nasdaq compliance deadlines and the outcome of the strategic alternatives review.
- Verify REM-001 study enrollment, grant reimbursement and performance conditions, and the timing and cost of further clinical development.
- Assess the consequences of the VAL-083 termination and any future royalties from Valent, which depend on subsequent commercialization.